JP2016512558A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512558A5 JP2016512558A5 JP2016501870A JP2016501870A JP2016512558A5 JP 2016512558 A5 JP2016512558 A5 JP 2016512558A5 JP 2016501870 A JP2016501870 A JP 2016501870A JP 2016501870 A JP2016501870 A JP 2016501870A JP 2016512558 A5 JP2016512558 A5 JP 2016512558A5
- Authority
- JP
- Japan
- Prior art keywords
- butoxy
- tert
- acetic acid
- alkyl
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 54
- 125000000217 alkyl group Chemical group 0.000 claims 35
- -1 homopiperidinyl Chemical group 0.000 claims 30
- 125000001475 halogen functional group Chemical group 0.000 claims 20
- 125000001188 haloalkyl group Chemical group 0.000 claims 18
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 17
- 125000001424 substituent group Chemical group 0.000 claims 16
- 125000003545 alkoxy group Chemical group 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000004438 haloalkoxy group Chemical group 0.000 claims 12
- 125000003342 alkenyl group Chemical group 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 125000003302 alkenyloxy group Chemical group 0.000 claims 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 239000003112 inhibitor Substances 0.000 claims 7
- 125000003386 piperidinyl group Chemical group 0.000 claims 7
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000002541 furyl group Chemical group 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 6
- 125000002883 imidazolyl group Chemical group 0.000 claims 6
- 125000001786 isothiazolyl group Chemical group 0.000 claims 6
- 125000000842 isoxazolyl group Chemical group 0.000 claims 6
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 6
- 125000002971 oxazolyl group Chemical group 0.000 claims 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims 6
- 125000000168 pyrrolyl group Chemical group 0.000 claims 6
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 6
- 125000000335 thiazolyl group Chemical group 0.000 claims 6
- 125000001544 thienyl group Chemical group 0.000 claims 6
- 125000001425 triazolyl group Chemical group 0.000 claims 6
- 125000002393 azetidinyl group Chemical group 0.000 claims 5
- 125000002757 morpholinyl group Chemical group 0.000 claims 5
- 125000004193 piperazinyl group Chemical group 0.000 claims 5
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 208000031886 HIV Infections Diseases 0.000 claims 4
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 claims 4
- 208000037357 HIV infectious disease Diseases 0.000 claims 4
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 4
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 4
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 4
- 125000001041 indolyl group Chemical group 0.000 claims 4
- 239000002777 nucleoside Substances 0.000 claims 4
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 4
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 2
- 229940099797 HIV integrase inhibitor Drugs 0.000 claims 2
- 229940122440 HIV protease inhibitor Drugs 0.000 claims 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 2
- 125000004450 alkenylene group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 230000034303 cell budding Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000002835 hiv fusion inhibitor Substances 0.000 claims 2
- 239000003084 hiv integrase inhibitor Substances 0.000 claims 2
- 239000004030 hiv protease inhibitor Substances 0.000 claims 2
- 230000035800 maturation Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- IXEPTGRMARFENT-HKBQPEDESA-N (2S)-2-[2-[(4-fluoro-3-methylphenyl)methylcarbamoyl]-6-methyl-4-(2-oxa-8-azatricyclo[7.3.1.05,13]trideca-1(13),5,7,9,11-pentaen-10-yl)pyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C1=C(F)C(C)=CC(CNC(=O)C2=NN3C=C(C)C([C@H](OC(C)(C)C)C(O)=O)=C(C=4C=5N=CC=C6CCOC(C=56)=CC=4)C3=C2)=C1 IXEPTGRMARFENT-HKBQPEDESA-N 0.000 claims 1
- GXHHOTNIDWJTAS-XIFFEERXSA-N (2S)-2-[2-[4-[(4-fluorophenyl)methyl]pyrazol-1-yl]-6-methyl-4-(2-oxa-8-azatricyclo[7.3.1.05,13]trideca-1(13),5,7,9,11-pentaen-10-yl)pyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C1=C2C(C=3C=4N=CC=C5CCOC(C=45)=CC=3)=C([C@H](OC(C)(C)C)C(O)=O)C(C)=CN2N=C1N(N=C1)C=C1CC1=CC=C(F)C=C1 GXHHOTNIDWJTAS-XIFFEERXSA-N 0.000 claims 1
- WAOBEXMKRVBRQA-YTTGMZPUSA-N (2S)-2-[2-[5-[(4-fluorophenyl)methyl]-1,3-oxazol-2-yl]-6-methyl-4-(2-oxa-8-azatricyclo[7.3.1.05,13]trideca-1(13),5,7,9,11-pentaen-10-yl)pyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C1=C2C(C=3C=4N=CC=C5CCOC(C=45)=CC=3)=C([C@H](OC(C)(C)C)C(O)=O)C(C)=CN2N=C1C(O1)=NC=C1CC1=CC=C(F)C=C1 WAOBEXMKRVBRQA-YTTGMZPUSA-N 0.000 claims 1
- SRRAXFGSMNTMDJ-YTTGMZPUSA-N (2S)-2-[2-[5-[(4-fluorophenyl)methyl]-1,3-thiazol-2-yl]-6-methyl-4-(2-oxa-8-azatricyclo[7.3.1.05,13]trideca-1(13),5,7,9,11-pentaen-10-yl)pyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C1=C2C(C=3C=4N=CC=C5CCOC(C=45)=CC=3)=C([C@H](OC(C)(C)C)C(O)=O)C(C)=CN2N=C1C(S1)=NC=C1CC1=CC=C(F)C=C1 SRRAXFGSMNTMDJ-YTTGMZPUSA-N 0.000 claims 1
- WLFXWNMWPYJDJD-PMERELPUSA-N (2S)-2-[4-(8-fluoro-5-methyl-3,4-dihydro-2H-chromen-6-yl)-2-[(4-fluoro-3-methylphenyl)methylcarbamoyl]-6-methylpyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound Cc1cc(CNC(=O)c2cc3c(-c4cc(F)c5OCCCc5c4C)c([C@H](OC(C)(C)C)C(O)=O)c(C)cn3n2)ccc1F WLFXWNMWPYJDJD-PMERELPUSA-N 0.000 claims 1
- JAORABFFBCNCEO-SANMLTNESA-N (2s)-2-[10-(8-fluoro-5-methyl-3,4-dihydro-2h-chromen-6-yl)-8-methylpyrido[1,2-b]indazol-9-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound O1CCCC2=C(C)C(C=3C4=C5C=CC=CC5=NN4C=C(C=3[C@H](OC(C)(C)C)C(O)=O)C)=CC(F)=C21 JAORABFFBCNCEO-SANMLTNESA-N 0.000 claims 1
- ULHWBJXCIRQVCU-SANMLTNESA-N (2s)-2-[2-(3-bromophenyl)-6-methyl-4-(4-methyl-4-prop-2-enoxypiperidin-1-yl)pyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=CN2N=C(C=3C=C(Br)C=CC=3)C=C2C=1N1CCC(C)(OCC=C)CC1 ULHWBJXCIRQVCU-SANMLTNESA-N 0.000 claims 1
- WRFUXBIIMNVOGZ-SNFDCCKOSA-N (2s)-2-[2-[3-[2-fluoro-3-methyl-6-[(2s)-pentan-2-yl]oxyphenyl]phenyl]-6-methyl-4-(4-methyl-4-propoxypiperidin-1-yl)pyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C1CC(OCCC)(C)CCN1C1=C([C@H](OC(C)(C)C)C(O)=O)C(C)=CN2C1=CC(C=1C=C(C=CC=1)C=1C(=CC=C(C)C=1F)O[C@@H](C)CCC)=N2 WRFUXBIIMNVOGZ-SNFDCCKOSA-N 0.000 claims 1
- SLZYXZFOBJKSSS-SANMLTNESA-N (2s)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-[(4-fluoro-3-methylphenyl)methylcarbamoyl]-6-methylpyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C1=C(F)C(C)=CC(CNC(=O)C2=NN3C=C(C)C([C@H](OC(C)(C)C)C(O)=O)=C(N4CCC(C)(C)CC4)C3=C2)=C1 SLZYXZFOBJKSSS-SANMLTNESA-N 0.000 claims 1
- CBDSJKSTELMHIB-NDEPHWFRSA-N (2s)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-[4-[(4-fluorophenyl)methyl]pyrazol-1-yl]-6-methylpyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=CN2N=C(N3N=CC(CC=4C=CC(F)=CC=4)=C3)C=C2C=1N1CCC(C)(C)CC1 CBDSJKSTELMHIB-NDEPHWFRSA-N 0.000 claims 1
- NVXPQGHMBBOOKZ-MHZLTWQESA-N (2s)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-[5-[(4-fluorophenyl)methyl]-1,3-oxazol-2-yl]-6-methylpyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=CN2N=C(C=3OC(CC=4C=CC(F)=CC=4)=CN=3)C=C2C=1N1CCC(C)(C)CC1 NVXPQGHMBBOOKZ-MHZLTWQESA-N 0.000 claims 1
- KPPZTAGBWZZHPW-MHZLTWQESA-N (2s)-2-[4-(4,4-dimethylpiperidin-1-yl)-2-[5-[(4-fluorophenyl)methyl]-1,3-thiazol-2-yl]-6-methylpyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=CN2N=C(C=3SC(CC=4C=CC(F)=CC=4)=CN=3)C=C2C=1N1CCC(C)(C)CC1 KPPZTAGBWZZHPW-MHZLTWQESA-N 0.000 claims 1
- IMMDGLXLSLMURK-LJAQVGFWSA-N (2s)-2-[4-(4,4-dimethylpiperidin-1-yl)-6-methyl-2-(3-pyridin-3-ylphenyl)pyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=CN2N=C(C=3C=C(C=CC=3)C=3C=NC=CC=3)C=C2C=1N1CCC(C)(C)CC1 IMMDGLXLSLMURK-LJAQVGFWSA-N 0.000 claims 1
- SVDHERPQDVBDEQ-NDEPHWFRSA-N (2s)-2-[4-(5-chloro-3,4-dihydro-2h-1,4-benzoxazin-6-yl)-2-[(4-fluoro-3-methylphenyl)methylcarbamoyl]-6-methylpyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C1=C(F)C(C)=CC(CNC(=O)C2=NN3C=C(C)C([C@H](OC(C)(C)C)C(O)=O)=C(C=4C(=C5NCCOC5=CC=4)Cl)C3=C2)=C1 SVDHERPQDVBDEQ-NDEPHWFRSA-N 0.000 claims 1
- YDLOXOOSLPJIAD-PMERELPUSA-N (2s)-2-[4-(5-chloro-3,4-dihydro-2h-1,4-benzoxazin-6-yl)-2-[4-[(4-fluorophenyl)methyl]pyrazol-1-yl]-6-methylpyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C1=C2C(C=3C(=C4NCCOC4=CC=3)Cl)=C([C@H](OC(C)(C)C)C(O)=O)C(C)=CN2N=C1N(N=C1)C=C1CC1=CC=C(F)C=C1 YDLOXOOSLPJIAD-PMERELPUSA-N 0.000 claims 1
- WWVITSNUKPEINU-LJAQVGFWSA-N (2s)-2-[4-(5-chloro-3,4-dihydro-2h-1,4-benzoxazin-6-yl)-2-[5-[(4-fluorophenyl)methyl]-1,3-oxazol-2-yl]-6-methylpyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C1=C2C(C=3C(=C4NCCOC4=CC=3)Cl)=C([C@H](OC(C)(C)C)C(O)=O)C(C)=CN2N=C1C(O1)=NC=C1CC1=CC=C(F)C=C1 WWVITSNUKPEINU-LJAQVGFWSA-N 0.000 claims 1
- WCCOFXGPMUKLIR-LJAQVGFWSA-N (2s)-2-[4-(5-chloro-3,4-dihydro-2h-1,4-benzoxazin-6-yl)-2-[5-[(4-fluorophenyl)methyl]-1,3-thiazol-2-yl]-6-methylpyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C1=C2C(C=3C(=C4NCCOC4=CC=3)Cl)=C([C@H](OC(C)(C)C)C(O)=O)C(C)=CN2N=C1C(S1)=NC=C1CC1=CC=C(F)C=C1 WCCOFXGPMUKLIR-LJAQVGFWSA-N 0.000 claims 1
- BKIBDBSJHHXSKA-HKBQPEDESA-N (2s)-2-[4-(5-chloro-3,4-dihydro-2h-1,4-benzoxazin-6-yl)-6-methyl-2-(3-pyridin-3-ylphenyl)pyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C1=C2C(C=3C(=C4NCCOC4=CC=3)Cl)=C([C@H](OC(C)(C)C)C(O)=O)C(C)=CN2N=C1C(C=1)=CC=CC=1C1=CC=CN=C1 BKIBDBSJHHXSKA-HKBQPEDESA-N 0.000 claims 1
- NVJFHRRQLBAVPZ-XIFFEERXSA-N (2s)-2-[4-(5-chloro-3,4-dihydro-2h-1,4-benzoxazin-6-yl)-6-methyl-2-[3-(2-methylphenyl)phenyl]pyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC1=CC=CC=C1C1=CC=CC(C2=NN3C=C(C)C([C@H](OC(C)(C)C)C(O)=O)=C(C=4C(=C5NCCOC5=CC=4)Cl)C3=C2)=C1 NVJFHRRQLBAVPZ-XIFFEERXSA-N 0.000 claims 1
- FGHYDWDTGCEFGN-HKBQPEDESA-N (2s)-2-[4-(8-fluoro-5-methyl-3,4-dihydro-2h-chromen-6-yl)-2-[5-[(4-fluorophenyl)methyl]-1,3-oxazol-2-yl]-6-methylpyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C1=C2C(C=3C(=C4CCCOC4=C(F)C=3)C)=C([C@H](OC(C)(C)C)C(O)=O)C(C)=CN2N=C1C(O1)=NC=C1CC1=CC=C(F)C=C1 FGHYDWDTGCEFGN-HKBQPEDESA-N 0.000 claims 1
- YKGGXUFXZCSKHI-HKBQPEDESA-N (2s)-2-[4-(8-fluoro-5-methyl-3,4-dihydro-2h-chromen-6-yl)-2-[5-[(4-fluorophenyl)methyl]-1,3-thiazol-2-yl]-6-methylpyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C1=C2C(C=3C(=C4CCCOC4=C(F)C=3)C)=C([C@H](OC(C)(C)C)C(O)=O)C(C)=CN2N=C1C(S1)=NC=C1CC1=CC=C(F)C=C1 YKGGXUFXZCSKHI-HKBQPEDESA-N 0.000 claims 1
- DZVRFPSOOQHJFK-XIFFEERXSA-N (2s)-2-[4-(8-fluoro-5-methyl-3,4-dihydro-2h-chromen-6-yl)-6-methyl-2-(3-pyridin-3-ylphenyl)pyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C1=C2C(C=3C(=C4CCCOC4=C(F)C=3)C)=C([C@H](OC(C)(C)C)C(O)=O)C(C)=CN2N=C1C(C=1)=CC=CC=1C1=CC=CN=C1 DZVRFPSOOQHJFK-XIFFEERXSA-N 0.000 claims 1
- QETAKGCWTITPHK-DHUJRADRSA-N (2s)-2-[4-(8-fluoro-5-methyl-3,4-dihydro-2h-chromen-6-yl)-6-methyl-2-[3-(2-methylphenyl)phenyl]pyrazolo[1,5-a]pyridin-5-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC1=CC=CC=C1C1=CC=CC(C2=NN3C=C(C)C([C@H](OC(C)(C)C)C(O)=O)=C(C=4C(=C5CCCOC5=C(F)C=4)C)C3=C2)=C1 QETAKGCWTITPHK-DHUJRADRSA-N 0.000 claims 1
- ALLIZEAXNXSFGD-UHFFFAOYSA-N 1-methyl-2-phenylbenzene Chemical compound CC1=CC=CC=C1C1=CC=CC=C1 ALLIZEAXNXSFGD-UHFFFAOYSA-N 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361781764P | 2013-03-14 | 2013-03-14 | |
| US61/781,764 | 2013-03-14 | ||
| PCT/US2014/025525 WO2014159959A1 (en) | 2013-03-14 | 2014-03-13 | Inhibitors of human immunodeficiency virus replication |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016512558A JP2016512558A (ja) | 2016-04-28 |
| JP2016512558A5 true JP2016512558A5 (enExample) | 2017-03-09 |
Family
ID=50842317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501870A Pending JP2016512558A (ja) | 2013-03-14 | 2014-03-13 | ヒト免疫不全ウイルス複製の阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9527842B2 (enExample) |
| EP (1) | EP2970274B1 (enExample) |
| JP (1) | JP2016512558A (enExample) |
| CN (1) | CN105189503B (enExample) |
| ES (1) | ES2623904T3 (enExample) |
| WO (1) | WO2014159959A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9944656B2 (en) | 2014-02-12 | 2018-04-17 | VIIV Healthcare UK (No.5) Limited | Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication |
| ES2687322T3 (es) | 2014-02-19 | 2018-10-24 | VIIV Healthcare UK (No.5) Limited | Inhibidores de la replicación del virus de inmunodeficiencia humana |
| US9193720B2 (en) | 2014-02-20 | 2015-11-24 | Bristol-Myers Squibb Company | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| US9975906B2 (en) | 2014-05-16 | 2018-05-22 | Shionogi & Co., Ltd. | Tricyclic heterocycle derivatives having HIV replication inhibitory effect |
| CA2987384A1 (en) | 2015-05-29 | 2016-12-08 | Shionogi & Co., Ltd. | Nitrogen-containing tricyclic derivative having hiv replication inhibitory activity |
| CN107820493A (zh) | 2015-07-06 | 2018-03-20 | Viiv保健英国第五有限公司 | 作为人类免疫缺陷性病毒复制的抑制剂的吡啶‑3‑基乙酸衍生物 |
| KR20180025926A (ko) | 2015-07-08 | 2018-03-09 | 비브 헬스케어 유케이 (넘버5) 리미티드 | 인간 면역결핍 바이러스 복제의 억제제로서의 피리딘-3-일 아세트산 유도체 |
| AU2016290205A1 (en) | 2015-07-09 | 2018-01-18 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| AU2016290986A1 (en) | 2015-07-09 | 2018-01-18 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| CN108137532A (zh) | 2015-08-07 | 2018-06-08 | Viiv保健英国第五有限公司 | 作为人免疫缺陷病毒复制的抑制剂的吡啶-3-基乙酸衍生物 |
| BR112018002681A2 (pt) | 2015-08-10 | 2019-04-24 | Viiv Healthcare Uk No 5 Ltd | ?composto, composição, e, método para tratamento de infecção por hiv? |
| TWI657086B (zh) | 2015-08-11 | 2019-04-21 | 英商Viiv醫療保健英國(No.5)有限公司 | 做為人類免疫缺陷病毒複製抑制劑之５－（ｎ－苯甲基四氫異喹啉－６－基）吡啶－３－基乙酸衍生物 |
| CN108137552A (zh) | 2015-08-12 | 2018-06-08 | Viiv保健英国第五有限公司 | 作为人免疫缺陷病毒复制的抑制剂的5-(n-稠合三环芳基四氢异喹啉-6-基)吡啶-3-基乙酸衍生物 |
| TW201718537A (zh) | 2015-08-12 | 2017-06-01 | Ｖｉｉｖ醫療保健英國（Ｎｏ．５）有限公司 | 做為人類免疫缺陷病毒複製抑制劑之吡啶－３－基乙酸衍生物 |
| CN108137553A (zh) | 2015-08-12 | 2018-06-08 | Viiv保健英国第五有限公司 | 作为人免疫缺陷病毒复制的抑制剂的5-(n-[6,5]-稠合双环芳基四氢异喹啉-6-基)吡啶-3-基乙酸衍生物 |
| JP2018523695A (ja) | 2015-08-20 | 2018-08-23 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体 |
| MA52119A (fr) | 2015-10-19 | 2018-08-29 | Ncyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| PT3377488T (pt) | 2015-11-19 | 2022-11-21 | Incyte Corp | Compostos heterocíclicos como imunomoduladores |
| SI3394033T1 (sl) | 2015-12-22 | 2021-03-31 | Incyte Corporation | Heterociklične spojine kot imunomodulatorji |
| WO2017192961A1 (en) | 2016-05-06 | 2017-11-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2017195111A1 (en) | 2016-05-11 | 2017-11-16 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| WO2017195113A1 (en) | 2016-05-11 | 2017-11-16 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| WO2017195112A1 (en) | 2016-05-11 | 2017-11-16 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| EP3464279B1 (en) | 2016-05-26 | 2021-11-24 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| PL3472167T3 (pl) | 2016-06-20 | 2022-12-19 | Incyte Corporation | Związki heterocykliczne jako immunomodulatory |
| EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2941716T3 (es) | 2016-08-29 | 2023-05-25 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| EP3558973B1 (en) | 2016-12-22 | 2021-09-15 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| MY197501A (en) | 2016-12-22 | 2023-06-19 | Incyte Corp | Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers |
| WO2018119286A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| KR102696516B1 (ko) | 2016-12-22 | 2024-08-22 | 인사이트 코포레이션 | 면역조절제로서의 벤조옥사졸 유도체 |
| US20180179201A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2018127801A1 (en) | 2017-01-03 | 2018-07-12 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| TW201835068A (zh) | 2017-01-03 | 2018-10-01 | 英商Viiv醫療保健英國(No.5)有限公司 | 作為人類免疫缺乏病毒複製之抑制劑之吡啶-3-基乙酸衍生物 |
| SG11201909882SA (en) | 2017-04-24 | 2019-11-28 | Nantcell Inc | Targeted neoepitope vectors and methods therefor |
| EP4212529B1 (en) | 2018-03-30 | 2025-01-29 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| FI4219492T3 (fi) | 2018-05-11 | 2025-02-17 | Incyte Corp | Heterosyklisiä yhdisteitä immunomodulaattoreina |
| WO2019244066A2 (en) | 2018-06-19 | 2019-12-26 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| WO2020003093A1 (en) | 2018-06-25 | 2020-01-02 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| CA3150434A1 (en) | 2019-08-09 | 2021-02-18 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
| AR120109A1 (es) | 2019-09-30 | 2022-02-02 | Incyte Corp | Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores |
| IL292524A (en) | 2019-11-11 | 2022-06-01 | Incyte Corp | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| PE20231438A1 (es) | 2020-11-06 | 2023-09-14 | Incyte Corp | Proceso para hacer un inhibidor de pd-1/pd-l1 y sales y formas cristalinas del mismo |
| WO2022099075A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Crystalline form of a pd-1/pd-l1 inhibitor |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7939545B2 (en) | 2006-05-16 | 2011-05-10 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| US8377960B2 (en) | 2007-11-15 | 2013-02-19 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| CA2705312C (en) | 2007-11-15 | 2013-06-25 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| US8461180B2 (en) | 2007-11-16 | 2013-06-11 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| NZ585226A (en) | 2007-11-16 | 2012-08-31 | Gilead Sciences Inc | Inhibitors of human immunodeficiency virus replication |
| CN101970741B (zh) | 2007-11-23 | 2014-09-03 | 皇家飞利浦电子股份有限公司 | 隔间 |
| GB0908394D0 (en) | 2009-05-15 | 2009-06-24 | Univ Leuven Kath | Novel viral replication inhibitors |
| US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| GB0913636D0 (en) | 2009-08-05 | 2009-09-16 | Univ Leuven Kath | Novel viral replication inhibitors |
| SG10201408512RA (en) | 2009-12-23 | 2015-02-27 | Univ Leuven Kath | Novel antiviral compounds |
| US9102614B2 (en) | 2010-07-02 | 2015-08-11 | Gilead Sciences, Inc. | Naphth-2-ylacetic acid derivatives to treat AIDS |
| WO2012003498A1 (en) | 2010-07-02 | 2012-01-05 | Gilead Sciences, Inc. | 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds |
| US8633200B2 (en) * | 2010-09-08 | 2014-01-21 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| EP2640729B1 (en) | 2010-11-15 | 2016-12-21 | VIIV Healthcare UK Limited | Inhibitors of hiv replication |
| NZ610315A (en) * | 2010-11-15 | 2015-08-28 | Univ Leuven Kath | Antiviral condensed heterocyclic compounds |
| US8791108B2 (en) | 2011-08-18 | 2014-07-29 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
-
2014
- 2014-03-13 ES ES14727271.0T patent/ES2623904T3/es active Active
- 2014-03-13 JP JP2016501870A patent/JP2016512558A/ja active Pending
- 2014-03-13 US US14/773,223 patent/US9527842B2/en not_active Expired - Fee Related
- 2014-03-13 EP EP14727271.0A patent/EP2970274B1/en not_active Not-in-force
- 2014-03-13 CN CN201480027109.2A patent/CN105189503B/zh not_active Expired - Fee Related
- 2014-03-13 WO PCT/US2014/025525 patent/WO2014159959A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512558A5 (enExample) | ||
| JP2016512507A5 (enExample) | ||
| JP2016512511A5 (enExample) | ||
| RU2420284C2 (ru) | Антагонист ccr5 для усиления иммуновосстановительной терапии и лечения оппортунистической инфекции у пациентов с вич | |
| HRP20191821T1 (hr) | Antiproliferativni spojevi i načini njihove uporabe | |
| JP2016512825A5 (enExample) | ||
| JP2016516692A5 (enExample) | ||
| JP2017526748A5 (enExample) | ||
| JP2019501133A5 (enExample) | ||
| JP2016528301A5 (enExample) | ||
| JP2016538313A5 (enExample) | ||
| NO20075682L (no) | Sammensetninger omfattende et oralt aktivt 1,2,4-oksadiazol for nonsense mutasjonsundertrykkelsesterapi | |
| JP2007519649A5 (enExample) | ||
| JP2017528494A (ja) | ｓＧＣ刺激剤 | |
| JP2016535795A5 (enExample) | ||
| RU2017107715A (ru) | Производные имидазо[1,2-a]пиридина для применения в качестве ингибиторов репликации вируса иммунодефицита человека | |
| RU2015120216A (ru) | Ингибиторы тирозинкиназы брутона | |
| JP2016506961A5 (enExample) | ||
| JP2015524841A5 (enExample) | ||
| JP2011513475A5 (enExample) | ||
| NO20091826L (no) | Fremgangsmater for dosering av oralt aktive 1,2,4-oksadiazol for nonsense mutasjonsuppresjonsterapi | |
| JP2014532754A5 (enExample) | ||
| IL257240A (en) | History of 5– (n– benzyl tetrahydroisoquinoline – 6 – il) Pyridine – 3 – il Acetic acid as inhibitors of human immunodeficiency virus replication | |
| MX2015017629A (es) | Combinaciones farmaceuticas. | |
| RU2016142611A (ru) | Пролекарственные средства ингибиторов обратной транскриптазы вич |